Abstract Search

ea0098c46 | Clinical – Surgery/Applied Pathology | NANETS2023

Peptide receptor radionuclide therapy improves survival in patients who progress after resection of gastroenteropancreatic neuroendocrine tumors

Borbon Luis C. , Sherman Scott K. , Breheny Patrick , Ear Po H. , Menda Yusuf , Chandrasekharan Chandrikha , Bellizzi Andrew M. , O'Dorisio Thomas M. , Dillon Joseph S. , Howe James R

Background: Peptide Receptor Radionuclide Therapy (PRRT) is effective for gastroenteropancreatic (GEP) neuroendocrine tumors (NETs) and received FDA approval after demonstrating improved progression-free-survival (PFS) in advanced midgut NETs. We investigated a two-decade experience with PRRT, hypothesizing that PRRT confers PFS and overall-survival (OS) advantages in patients who progress after surgery.Methods: A single-institutional NET database was re...

0 shares

Endocrine Abstracts

Peptide receptor radionuclide therapy improves survival in patients who progress after resection of gastroenteropancreatic neuroendocrine tumors

BiosciAbstracts